S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead

ADC Therapeutics (ADCT) Earnings Date, Estimates & Call Transcripts

$4.36
-0.03 (-0.68%)
(As of 04/15/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 14Estimated
Actual EPS
(Mar. 13)
-$1.03 Missed By -$0.56
Consensus EPS
(Mar. 13)
-$0.47
Skip Charts & View Estimated and Actual Earnings Data

ADCT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ADCT Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

ADC Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($0.53)($0.53)($0.53)
Q2 20241($0.54)($0.54)($0.54)
Q3 20241($0.55)($0.55)($0.55)
Q4 20241($0.55)($0.55)($0.55)
FY 20244($2.17)($2.17)($2.17)

ADCT Earnings Date and Information

ADC Therapeutics last released its quarterly earnings data on March 13th, 2024. The reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by $0.56. The firm earned $16.79 million during the quarter, compared to the consensus estimate of $16.58 million. ADC Therapeutics has generated ($2.93) earnings per share over the last year (($2.93) diluted earnings per share). Earnings for ADC Therapeutics are expected to grow in the coming year, from ($2.19) to ($1.64) per share. ADC Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off prior year's report dates.

ADC Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/14/2024
Estimated)
------- 
3/13/2024Q4 2023($0.47)($1.03)($0.56)($1.03)$16.58 million$16.79 million
11/7/2023Q3 2023($0.61)($0.58)+$0.03($0.58)$14.57 million$14.49 million
8/8/2023Q2 2023($0.44)($0.58)($0.14)($0.58)$34.77 million$19.28 million
5/9/2023Q1 2023($0.80)($0.74)+$0.06($0.74)$20.10 million$18.99 million
2/28/2023Q4 2022($0.49)($0.30)+$0.19($0.30)$75.53 million$69.80 million
11/8/2022Q3 2022($0.51)($0.65)($0.14)($0.65)$55.61 million$76.32 million
8/9/2022Q2 2022($0.96)($0.84)+$0.12($0.84)$20.18 million$17.29 million    
5/9/2022Q1 2022($0.76)($0.22)+$0.54($0.22)$29.90 million$46.50 million    
3/3/2022Q4 2021($0.87)($0.45)+$0.42($0.45)$16.40 million$17.01 million    
11/2/2021Q3 2021($0.92)($0.93)($0.01)($0.93)$7.74 million$13.15 million    
8/2/2021Q2 2021($0.86)($0.96)($0.10)($0.95)$5.70 million$3.76 million    
5/5/2021Q1 2021($1.00)($0.46)+$0.54($0.67)--  

ADC Therapeutics Earnings - Frequently Asked Questions

When is ADC Therapeutics's earnings date?

ADC Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off last year's report dates. Learn more on ADCT's earnings history.

Did ADC Therapeutics beat their earnings estimates last quarter?

In the previous quarter, ADC Therapeutics (NYSE:ADCT) missed the analysts' consensus estimate of ($0.47) by $0.56 with a reported earnings per share (EPS) of ($1.03). Learn more on analysts' earnings estimate vs. ADCT's actual earnings.

How much revenue does ADC Therapeutics generate each year?

ADC Therapeutics (NYSE:ADCT) has a recorded annual revenue of $69.56 million.

How much profit does ADC Therapeutics generate each year?

ADC Therapeutics (NYSE:ADCT) has a recorded net income of -$240.05 million. ADCT has generated -$2.93 earnings per share over the last four quarters.

What is ADC Therapeutics's EPS forecast for next year?

ADC Therapeutics's earnings are expected to grow from ($2.19) per share to ($1.64) per share in the next year.


More Earnings Resources from MarketBeat

This page (NYSE:ADCT) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners